Michael Thomas Heffernan Sells 44,400 Shares of Collegium Pharmaceutical (COLL) Stock

Collegium Pharmaceutical (NASDAQ:COLL) Chairman Michael Thomas Heffernan sold 44,400 shares of the company’s stock in a transaction that occurred on Thursday, April 19th. The shares were sold at an average price of $26.00, for a total value of $1,154,400.00. Following the completion of the transaction, the chairman now directly owns 545,893 shares of the company’s stock, valued at $14,193,218. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Michael Thomas Heffernan also recently made the following trade(s):

  • On Tuesday, January 23rd, Michael Thomas Heffernan sold 20,000 shares of Collegium Pharmaceutical stock. The shares were sold at an average price of $25.01, for a total value of $500,200.00.

Shares of COLL stock traded down $0.45 during trading hours on Monday, hitting $24.22. The stock had a trading volume of 182,835 shares, compared to its average volume of 581,276. The company has a market capitalization of $814.79, a P/E ratio of -9.81 and a beta of 0.76. Collegium Pharmaceutical has a twelve month low of $7.37 and a twelve month high of $29.90.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its quarterly earnings data on Wednesday, March 7th. The specialty pharmaceutical company reported ($0.54) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.56) by $0.02. The business had revenue of $10.79 million during the quarter, compared to the consensus estimate of $9.88 million. Collegium Pharmaceutical had a negative return on equity of 73.00% and a negative net margin of 262.91%. The firm’s revenue was up 728.4% compared to the same quarter last year. equities research analysts expect that Collegium Pharmaceutical will post -0.74 EPS for the current fiscal year.

COLL has been the subject of a number of research analyst reports. BidaskClub downgraded Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a report on Tuesday, January 9th. Zacks Investment Research downgraded Collegium Pharmaceutical from a “buy” rating to a “hold” rating in a report on Friday, February 2nd. Needham & Company LLC upped their price target on Collegium Pharmaceutical from $28.00 to $35.00 and gave the company a “buy” rating in a report on Wednesday, February 7th. Piper Jaffray set a $33.00 price target on Collegium Pharmaceutical and gave the company a “buy” rating in a report on Tuesday, January 23rd. Finally, William Blair reaffirmed an “outperform” rating on shares of Collegium Pharmaceutical in a report on Thursday, March 8th. Nine research analysts have rated the stock with a buy rating, The stock presently has a consensus rating of “Buy” and a consensus target price of $30.83.

Several hedge funds have recently bought and sold shares of the company. Macquarie Group Ltd. boosted its holdings in shares of Collegium Pharmaceutical by 21.5% in the fourth quarter. Macquarie Group Ltd. now owns 1,616,117 shares of the specialty pharmaceutical company’s stock valued at $29,833,000 after acquiring an additional 286,138 shares during the period. LPL Financial LLC boosted its holdings in shares of Collegium Pharmaceutical by 6.4% in the fourth quarter. LPL Financial LLC now owns 151,085 shares of the specialty pharmaceutical company’s stock valued at $2,789,000 after acquiring an additional 9,082 shares during the period. Teachers Advisors LLC boosted its holdings in shares of Collegium Pharmaceutical by 11.3% in the fourth quarter. Teachers Advisors LLC now owns 66,533 shares of the specialty pharmaceutical company’s stock valued at $1,228,000 after acquiring an additional 6,739 shares during the period. Raymond James & Associates acquired a new stake in shares of Collegium Pharmaceutical in the fourth quarter valued at approximately $389,000. Finally, California State Teachers Retirement System boosted its holdings in shares of Collegium Pharmaceutical by 10.5% in the fourth quarter. California State Teachers Retirement System now owns 39,499 shares of the specialty pharmaceutical company’s stock valued at $729,000 after acquiring an additional 3,752 shares during the period. 86.33% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: “Michael Thomas Heffernan Sells 44,400 Shares of Collegium Pharmaceutical (COLL) Stock” was originally posted by Markets Daily and is owned by of Markets Daily. If you are accessing this article on another publication, it was copied illegally and republished in violation of United States & international trademark & copyright laws. The legal version of this article can be read at https://www.themarketsdaily.com/2018/04/23/michael-thomas-heffernan-sells-44400-shares-of-collegium-pharmaceutical-coll-stock.html.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and tampering, including chewing, crushing, and/or dissolving.

Insider Buying and Selling by Quarter for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply